

STUDY OF CHARACTERIZATION & ANTIFUNGAL SUSCEPTIBILITY TESTING OF CLINICALLY SIGNIFICANT CANDIDA SPECIESGeeta S. H¹**HOW TO CITE THIS ARTICLE:**

Geeta S. H. "Study of Characterization & Antifungal Susceptibility Testing of Clinically Significant Candida Species". Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 22, June 02; Page: 5973-5978, DOI: 10.14260/jemds/2014/2692

ABSTRACT: BACKGROUND: Over the last two decades Candida has accounted for the most serious opportunistic infections especially in the immuno-compromised individuals. Candida species have emerged as important causes of invasive infections & the rates of resistance to standard antifungal therapies are on the rise. Awareness regarding fungal infections has compelled the clinicians and laboratories to lay more emphasis on the detection of fungi; as speciation and antifungal tests are not routinely done. Over the past decade significant progress has been made with standardization of the methods for antifungal susceptibility testing, correlation between in-vitro results & patient outcome.

OBJECTIVES: The aim of this study was to isolate, identify & determine the susceptibility pattern of clinically significant Candida species and study the spectrum of Non-albicans Candida species, thus contributing to overall reduction in the cost of treatment and duration of hospital stay. **METHODS:** The study was carried out at department of microbiology MVJ Medical Hospital Bangalore for one year from Aug 2010 – July 2011. 50 Candida species which were isolated from various clinical specimens were included in the study. They were identified by using various media & identification methods. Antifungal susceptibility testing was done on Yeast nitrogen base agar by disk diffusion method & analyzed. **RESULTS:** Non-albicans Candida (NAC) emerged as the commonest species with [39(22%)] causing fungal infection followed by Candida albicans [11(22%)]. Among the NAC isolates Candida tropicalis was predominant followed by Candida krusei, Candida glabrata & Candida guilliermondi. **CONCLUSION:** Studying the speciation & susceptibility patterns of Candida will help us understand the etio-pathology and might assist in better patient care.

KEYWORDS: Candida, Characterization, Sugar assimilation / fermentation, Antifungal susceptibility.

INTRODUCTION: Candida species are ubiquitous in distribution & cause various localized, invasive and disseminated diseases in normal and compromised individuals. Due to the commensal nature of Candida, they usually cause endogenous infections. Candida species are increasingly being identified as opportunistic pathogens in recent years.

NAC has been observed to replace Candida albicans at most of the clinical sites of infection. These species are assuming importance due to their decreased resistance to commonly used antifungal agents & their potential to emerge as opportunistic nosocomial pathogens.^{1,2} The patients at extremes of age and with co-morbidities are at highest risk for invasive candidiasis. The co-infection of HIV with TB has increased the incidence of opportunistic fungal infections.^{3,4,5}

The increased frequency of non-albicans candida infection coupled with high levels of resistance to common antifungal drugs – are a cause of concern in prophylaxis and treatment of fungal infections. An early identification of Candida species provides an important help in selection of appropriate antifungal treatment.^{6,7}

ORIGINAL ARTICLE

MATERIALS & METHODS: 50 *Candida* species isolated from various clinical specimens of MVJ Medical College Bangalore, over a period of one year from Aug 2010 – July 2011 were included in the study. The samples were studied, isolated & identified to the species level using standard laboratory protocol. The preliminary identification was done by microscopy and isolation on SDA. The isolates were further speciated by germ tube test, corn meal agar morphology – chlamyospore formation & sugar assimilation / fermentation tests.^{8, 9, 10} Antifungal susceptibility testing by disk diffusion method was done on yeast nitrogen base agar for 4 antifungal agents [fluconazole, ketoconazole, itraconazole & amphotericin B] and analyzed. Antifungal susceptibility testing was done in accordance with CLSI document M44-A for yeasts.^{10, 11}

RESULTS: Among 50 *Candida* isolates, *Candida albicans* were 11 (22%) and NAC 39 (78%). The different species of *Candida* isolated were as shown in Table I. The age and sex distribution in *Candida* infections were shown in Table II and III respectively. The extremes of age were affected and incidence was seen predominantly in males.

Associated infections always have an immuno-suppressed/immuno-compromised factor contributing to it. Table IV shows candidiasis from different infections where the incidence of pulmonary infections were higher. Sample-wise distribution of *Candida* species is shown in table V.

Table VI shows antifungal susceptibility pattern to various antifungal agents.

Species of <i>Candida</i>	Isolated No	%
<i>Candida albicans</i>	11	22%
<i>Candida tropicalis</i>	20	40%
<i>Candida krusei</i>	8	16%
<i>Candida glabrata</i>	4	8%
<i>Candida guilliermondi</i>	3	6%
<i>Candida parapsilosis</i>	1	2%
<i>Candida kefyr</i>	3	6%

Table 1: Different species of *Candida* isolated

	1 -10	11 -20	21 -30	31 -40	41 -50	50+
<i>C. albicans</i>	3	-	1	1	3	3
NAC	4	-	3	5	8	20
Total	7	-	4	6	11	23

Table 2: Age Distribution – *Candida* species

Sex	%
Male	36 (72%)
Female	14 (28%)

Table 3: Sex Distribution – *Candida* species

ORIGINAL ARTICLE

Associated Infections	No.(%)
Tuberculosis / Pneumonia	26 (52%)
Diabetes mellitus	06 (12%)
HIV infection	07 (14%)
Pregnancy	01 (2%)
Nosocomial	03 (6%)
Others	07 (14%)
Total	50

Table 4: Candida and its associated infections

Samples	No. (%)
Sputum	26 (52%)
Faeces	09 (18%)
Pus	04 (8%)
Skin scrapings	03 (6%)
Ear swab	03 (6%)
Throat swab	01 (2%)
Urine	03 (6%)
Vaginal swab	01 (2%)
Total	50

Table 5: Candida species – Sample wise

Antifungal disk	C. albicans (11)	C tropicalis (20)	C krusei (8)	C glabrata (4)	C guillermondi (3)	C parapsilosis (1)	C kefyr (3)
Amphotericin B	S – 100%	S – 100%	S – 100%	S – 100%	S – 100%	S – 100%	S – 100%
Ketoconazole	S – 100%	S – 100%	I – 50%	S – 100%	S – 100%	S – 100%	S – 100%
Itraconazole	S – 100%	S – 60%	I – 30%	S – 40%	S – 70%	S – 60%	I – 50%
Fluconazole	S – 100%	S – 92%	R	S – 100%	S – 100%	S – 96%	S – 96%

Table 6: Susceptibility pattern of antifungal drugs

S – Sensitive I – Intermediate Sensitive R – Resistant

DISCUSSION: In the present study among NAC (78%), *C. tropicalis* emerged as the predominant isolate. In some of the other studies the % of *C. albicans* was higher than NAC which is in contrast to the present study. (Germian G & Pelletier R et al).¹² In our study, tuberculosis & pneumonia were the commonest pulmonary infections associated with candidiasis which was in accordance with other studies.(Bhramadatan K N et al).¹³ Oropharyngeal candidiasis (OPC) continues to be a common opportunistic infection in patients with HIV & is predictive of increasing immuno-suppression. The increasing use of fluconazole to treat HIV patients with OPC has resulted in a change in the prevalence of different candida species and the emergence of azole resistance.³

ORIGINAL ARTICLE

In the present study, the prevalence of candiduria caused by *Candida* species was 6% and women were affected predominantly. The higher prevalence in female patients may reflect vaginal candidiasis as the yeasts may ascend from genitor-urinary tract to urinary tract. The licensed antifungal agents [fluconazole, ketoconazole & Amphotericin B] were highly susceptible (96-100%) against most of the *Candida* species regardless of the age group. Itraconazole was less active than all of the other azoles against all species with the exception of *C. albicans* where its sensitivity was 100% in our study as observed in MA Pfaller¹ & RN Jones et al.¹⁴


CONCLUSION: Considerable increase in the incidence of candidiasis has been observed especially in critical care settings. NAC's are gradually gaining importance and replacing *C. albicans* as etiological agents. Early isolation & identification of candida and study of susceptibility pattern of antifungal drugs can be useful towards better management of candidiasis.

REFERENCES:



1. Krcmery V, Barnes AJ. Non albicans *Candida* species causing fungemia: pathogenicity and antifungal resistance. *J Hosp Infect.* 2002; 50: 243 – 260.
2. May J L, King A, Warren C A. Fluconazole disc diffusion testing for routine laboratory. *J Antimicrob Chemother.* 1997; 40: 511 – 560.
3. Shobha D Nadagir, Sneha K Chunchanur, LH Halesh¹, K Yasmeen, MR, Chandrashekar Patil. Significance of isolation and drug susceptibility testing of Non-*Candida albicans* species causing oropharyngeal candidiasis in HIV patients. *Southeast Asian J Trop Med Public health.* May 2008; Vol 39 (3): 492-95.
4. Narain S, Shastri J S, Mathur M, Mehta P R. Neonatal systemic candidiasis in a tertiary care centre: A brief communication. 2003; Vol 21 (1): 56 – 58.
5. Pinho Resende JC, De Resende MA, Saliba JL. Prevalence of *Candida* species in hospitalized patients and their factors. *Mycoses.* 2002; 45: 306.
6. Choudhary U et al. Rapid identification and Antifungal susceptibility pattern of *Candida* isolate. *Mycologia.* 2009; Vol 26 (2): 51-51.
7. Shivanand D, Saldanha D. Species identification of *Candida* isolates in various clinical specimens with their antifungal susceptibility patterns. *JCDR.* 2011; 5(6):1177–81.
8. Kwon-chung K J and J E Bennett. *Medical Mycology.* 1992. Lea & Febiger, Philadelphia.
9. Jagdish Chander. *Opportunistic Mycoses – Candidiasis; Text book of Medical Mycology,* 2008; 3rd Edn., 212-230.
10. National Committee for clinical laboratory standards. *Methods for Antifungal Disk diffusion susceptibility testing of yeasts: Approved standard M44-A (2012)* Wayne, PA, USA: NCCLS / CLSI. *Methods for Antifungal disk diffusion susceptibility testing of yeasts; Proposed guidelines.* CLSI document M44-P. CLSI, Pennsylvania, USA 2010.
11. Capoor MR, Nair D, Deb M, Verma PK, Srivatsava L, Aggarwal P. Emergence of Non-albicans *Candida* species and antifungal resistance in a tertiary care hospital. *Japanese J Infect Dis.* 2005 Dec; 58(6): 344 – 8.
12. St-Germain G, Laverdiere M, Pelletier R et al. Prevalence and antifungal susceptibility of 442 *Candida* isolates from blood and other normally sterile sites: Results of a 2 year (1996-1998)

ORIGINAL ARTICLE

- multicentric surveillance study in Quebec, Canada. *Journal of Clinical Microbiology*. 2001; 39: 949 – 95.
13. Jha BK, Dey S, Tamang MD, Joshy M, Shivanand PG, Bhramadatan KN. Characterization of *Candida* species isolated from cases of lower respiratory tract infection. *Kathmandu University Medical Journal*. 2006; Vol. 4, No. 3, Issue 15: 290-294.
14. MA Pfaller¹, DJ Diekema, RN Jones, SA Messer, RJ Hollis. Trends in Antifungal susceptibility of *Candida* species isolated from Pediatric and Adult patients with Blood stream infections: SENTRY Antimicrobial Surveillance Program. 1997-2000.



KOH wet mount showing fungal elements



**Gram stain – Pus cells & Pseudohyphae.
Chlamydoconidia on Corn meal agar [CMA]**



**CMA – Blastospores(singly/small groups)
with long pseudohyphae of *Candida tropicalis***

ORIGINAL ARTICLE



CMA – Clusters of blastospores along short hyphae of *Candida guilliermondii*



CMA – Giant hyphae with blastospores at the end seen in *Candida krusei*



CMA – blastospores without hyphae of *Candida glabrata*

AUTHORS:

1. Geeta S. H.

PARTICULARS OF CONTRIBUTORS:

1. Associate Professor, Department of Microbiology, M. V. J. Medical College, Hoskote, Bangalore.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Geeta S. H,
No. 54/5, Aurn Nivas Apts,
RMS Colony, Bhattarahalli,
Old Madras Road, Bangalore – 560049.
Email: drgeetashashikant@gmail.com

Date of Submission: 15/05/2014.

Date of Peer Review: 16/05/2014.

Date of Acceptance: 24/05/2014.

Date of Publishing: 27/05/2014.